Stating that the research and drug design, development and acceptance for introduction was indeed a challenging mission, he said that molecule to drug was the business of strong minds with the capacity to take calculated risks.
He said that information technology, biotechnology and nanotechnology were converging together to provide quality of service.
He asked Orchid to get into the research field, where convergence of technologies leads to development of new discoveries or new formulations. Kalam also urged the company to provide cost-effective world-class medical solutions.
